

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA: Nivolumab with cabozantinib for untreated advanced
or metastatic renal cell carcinoma**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

The following potential equality issues were highlighted:

- | |
|--|
| <ol style="list-style-type: none">1. Consultees commented that they would like to see people with rare subtypes of RCC included in the appraisal, since these people have the biggest unmet need for an effective treatment.2. How the treatment could be given at home or closer to home for patients unable to get to hospital due to physical or mental disability3. Equitable access to medication for all patients independent of geographic location4. Consideration of the impact of COVID-19 on patient care and treatment. |
|--|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

- | |
|---|
| <ul style="list-style-type: none">• Regarding point 1, NICE can only make recommendations for patient populations covered by the company's marketing authorisation. Where covered by the marketing authorisation and if evidence allows, rare subtypes of RCC may be considered within the appraisal. |
|---|

- Regarding points 2 and 3, access to hospitals or treatment centres is an implementation issue, it is not an equality issue that can be addressed by NICE recommendations.
- Regarding point 4, NICE has not been instructed by the Department of Health and Social Care to alter its methods to account for COVID-19.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name):Ross Dent.....

Date: 20 August 2020